New hope for older AML patients: shorter, safer transplant strategy

NCT ID NCT07046078

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This pilot study tests a new treatment plan for adults aged 60 and older with high-risk acute myeloid leukemia (AML) or similar blood cancers. The plan combines a strong chemotherapy regimen (FLAG-Ida) with a lower-intensity stem cell transplant just a few days later. The goal is to kill cancer cells effectively while shortening the time patients have dangerously low blood counts, which can lead to infections and other serious problems. The study will enroll 20 participants to see if this approach is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FLAG-Ida chemotherapy (fludarabine, cytarabine, G-CSF, idarubicin) followed by reduced-intensity total body irradiation and donor stem cell transplant
What this could lead to
If this works, it could offer a safer, more effective way to treat older adults with aggressive AML, potentially improving survival and reducing complications from low blood counts.
What could go wrong
This is a small, early-phase pilot study with only 20 participants. The approach is still experimental, and there are risks of infection, bleeding, and other serious side effects. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.